Company intelligence / Profile preview

Cellerys AG

Schlieren, Switzerland

Ownership: Private
Development stage: Phase 2

Overview

Cellerys has completed a successful Phase I clinical trial showing excellent tolerability and safety with indications of inducing tolerance mechanisms. Currently conducting a Phase I/II trial (RED4MS) that started in 2024 to demonstrate proof of concept for their immune tolerization therapy.

Therapeutic areas: Neurology
Modalities: Cell therapy
Industry: Biotech

Drug pipeline

3 assets

CLS12311

2 more assets in the full pipeline.

Request access →

Partnerships

NovartisNeogap TherapeuticsTETEC

Beyond the preview

Go deeper on Cellerys AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellerys AG.

Explore the full profile